Thermo Fisher Scientific Inc. $TMO Stock Sold by Whittier Trust Co.

Whittier Trust Co. lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 6.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,596 shares of the medical research company’s stock after selling 1,784 shares during the quarter. Whittier Trust Co.’s holdings in Thermo Fisher Scientific were worth $16,184,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $25,000. Allied Private Wealth LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $26,000. Compass Financial Management LLC raised its position in shares of Thermo Fisher Scientific by 137.5% in the 3rd quarter. Compass Financial Management LLC now owns 38 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 22 shares during the period. Pingora Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $30,000. Finally, Navigoe LLC bought a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $31,000. Institutional investors own 89.23% of the company’s stock.

Key Headlines Impacting Thermo Fisher Scientific

Investors following TMO have been watching these headlines:

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 2,831 shares of the business’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $706.45, for a total value of $1,999,959.95. Following the sale, the vice president directly owned 11,560 shares in the company, valued at $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TMO. Evercore decreased their price objective on shares of Thermo Fisher Scientific from $720.00 to $615.00 and set an “outperform” rating for the company in a report on Wednesday, October 28th. Argus increased their target price on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Citigroup lifted their price target on shares of Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a research report on Friday, October 23rd. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $723.00 to $756.00 and gave the company an “outperform” rating in a report on Thursday, October 22nd. Finally, Sanford C. Bernstein upped their price objective on shares of Thermo Fisher Scientific from $520.00 to $575.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $683.64.

Read Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $668.89 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $727.56. The company’s 50 day moving average price is $678.63 and its two-hundred day moving average price is $559.30. The company has a market capitalization of $247.84 billion, a P/E ratio of 35.28, a price-to-earnings-growth ratio of 2.82 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. The company had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.79 earnings per share. On average, analysts expect that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be paid a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.92%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Recommended Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.